Literature DB >> 29272550

Different contributions of chemokine N-terminal features attest to a different ligand binding mode and a bias towards activation of ACKR3/CXCR7 compared with CXCR4 and CXCR3.

Martyna Szpakowska1, Amanda M Nevins2, Max Meyrath1, David Rhainds3,4, Thomas D'huys5, François Guité-Vinet3,4, Nadine Dupuis6, Pierre-Arnaud Gauthier1, Manuel Counson1, Andrew Kleist2, Geneviève St-Onge3, Julien Hanson6, Dominique Schols5, Brian F Volkman2, Nikolaus Heveker3,4, Andy Chevigné1.   

Abstract

BACKGROUND AND
PURPOSE: Chemokines and their receptors form an intricate interaction and signalling network that plays critical roles in various physiological and pathological cellular processes. The high promiscuity and apparent redundancy of this network makes probing individual chemokine/receptor interactions and functional effects, as well as targeting individual receptor axes for therapeutic applications, challenging. Despite poor sequence identity, the N-terminal regions of chemokines, which play a key role in their activity and selectivity, contain several conserved features. Thus far little is known regarding the molecular basis of their interactions with typical and atypical chemokine receptors or the conservation of their contributions across chemokine-receptor pairs. EXPERIMENTAL APPROACH: We used a broad panel of chemokine variants and modified peptides derived from the N-terminal region of chemokines CXCL12, CXCL11 and vCCL2, to compare the contributions of various features to binding and activation of their shared receptors, the two typical, canonical G protein-signalling receptors, CXCR4 and CXCR3, as well as the atypical scavenger receptor CXCR7/ACKR3, which shows exclusively arrestin-dependent activity. KEY
RESULTS: We provide molecular insights into the plasticity of the ligand-binding pockets of these receptors, their chemokine binding modes and their activation mechanisms. Although the chemokine N-terminal region is a critical determinant, neither the most proximal residues nor the N-loop are essential for binding and activation of ACKR3, as distinct from binding and activation of CXCR4 and CXCR3. CONCLUSION AND IMPLICATIONS: These results suggest a different interaction mechanism between this atypical receptor and its ligands and illustrate its strong propensity to activation.
© 2017 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29272550      PMCID: PMC5900987          DOI: 10.1111/bph.14132

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  77 in total

1.  The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes.

Authors:  Karl Balabanian; Bernard Lagane; Simona Infantino; Ken Y C Chow; Julie Harriague; Barbara Moepps; Fernando Arenzana-Seisdedos; Marcus Thelen; Françoise Bachelerie
Journal:  J Biol Chem       Date:  2005-08-17       Impact factor: 5.157

2.  Synthesis, modeling and functional activity of substituted styrene-amides as small-molecule CXCR7 agonists.

Authors:  Maikel Wijtmans; David Maussang; Francesco Sirci; Danny J Scholten; Meritxell Canals; Azra Mujić-Delić; Milagros Chong; Kristell L S Chatalic; Hans Custers; Elwin Janssen; Chris de Graaf; Martine J Smit; Iwan J P de Esch; Rob Leurs
Journal:  Eur J Med Chem       Date:  2012-02-27       Impact factor: 6.514

3.  Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties.

Authors:  P Proost; E Schutyser; P Menten; S Struyf; A Wuyts; G Opdenakker; M Detheux; M Parmentier; C Durinx; A M Lambeir; J Neyts; S Liekens; P C Maudgal; A Billiau; J Van Damme
Journal:  Blood       Date:  2001-12-15       Impact factor: 22.113

4.  A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus.

Authors:  T N Kledal; M M Rosenkilde; F Coulin; G Simmons; A H Johnsen; S Alouani; C A Power; H R Lüttichau; J Gerstoft; P R Clapham; I Clark-Lewis; T N Wells; T W Schwartz
Journal:  Science       Date:  1997-09-12       Impact factor: 47.728

5.  N-terminal peptides of stromal cell-derived factor-1 with CXC chemokine receptor 4 agonist and antagonist activities.

Authors:  P Loetscher; J H Gong; B Dewald; M Baggiolini; I Clark-Lewis
Journal:  J Biol Chem       Date:  1998-08-28       Impact factor: 5.157

6.  Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1alpha.

Authors:  P Proost; S Struyf; D Schols; C Durinx; A Wuyts; J P Lenaerts; E De Clercq; I De Meester; J Van Damme
Journal:  FEBS Lett       Date:  1998-07-31       Impact factor: 4.124

7.  Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration.

Authors:  Paul Proost; Anneleen Mortier; Tamara Loos; Jo Vandercappellen; Mieke Gouwy; Isabelle Ronsse; Evemie Schutyser; Willy Put; Marc Parmentier; Sofie Struyf; Jo Van Damme
Journal:  Blood       Date:  2007-03-15       Impact factor: 22.113

8.  Structural biology. Structural basis for chemokine recognition and activation of a viral G protein-coupled receptor.

Authors:  John S Burg; Jessica R Ingram; A J Venkatakrishnan; Kevin M Jude; Abhiram Dukkipati; Evan N Feinberg; Alessandro Angelini; Deepa Waghray; Ron O Dror; Hidde L Ploegh; K Christopher Garcia
Journal:  Science       Date:  2015-03-06       Impact factor: 47.728

9.  A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development.

Authors:  Jennifer M Burns; Bretton C Summers; Yu Wang; Anita Melikian; Rob Berahovich; Zhenhua Miao; Mark E T Penfold; Mary Jean Sunshine; Dan R Littman; Calvin J Kuo; Kevin Wei; Brian E McMaster; Kim Wright; Maureen C Howard; Thomas J Schall
Journal:  J Exp Med       Date:  2006-08-28       Impact factor: 14.307

Review 10.  Biased and g protein-independent signaling of chemokine receptors.

Authors:  Anne Steen; Olav Larsen; Stefanie Thiele; Mette M Rosenkilde
Journal:  Front Immunol       Date:  2014-06-23       Impact factor: 7.561

View more
  22 in total

1.  NanoLuc-Based Methods to Measure β-Arrestin2 Recruitment to G Protein-Coupled Receptors.

Authors:  Xiaoyuan Ma; Rob Leurs; Henry F Vischer
Journal:  Methods Mol Biol       Date:  2021

2.  A dynamic and screening-compatible nanoluciferase-based complementation assay enables profiling of individual GPCR-G protein interactions.

Authors:  Céline Laschet; Nadine Dupuis; Julien Hanson
Journal:  J Biol Chem       Date:  2018-12-28       Impact factor: 5.157

Review 3.  What doesn't kill you makes you stranger: Dipeptidyl peptidase-4 (CD26) proteolysis differentially modulates the activity of many peptide hormones and cytokines generating novel cryptic bioactive ligands.

Authors:  Ahmed M Elmansi; Mohamed E Awad; Nada H Eisa; Dmitry Kondrikov; Khaled A Hussein; Alexandra Aguilar-Pérez; Samuel Herberg; Sudharsan Periyasamy-Thandavan; Sadanand Fulzele; Mark W Hamrick; Meghan E McGee-Lawrence; Carlos M Isales; Brian F Volkman; William D Hill
Journal:  Pharmacol Ther       Date:  2019-02-10       Impact factor: 12.310

4.  Assessment of Biased Agonism among Distinct Synthetic Cannabinoid Receptor Agonist Scaffolds.

Authors:  Elise Wouters; Jolien Walraed; Michael Joseph Robertson; Max Meyrath; Martyna Szpakowska; Andy Chevigné; Georgios Skiniotis; Christophe Stove
Journal:  ACS Pharmacol Transl Sci       Date:  2019-11-04

Review 5.  Emerging roles of atypical chemokine receptor 3 (ACKR3) in normal development and physiology.

Authors:  K E Quinn; D I Mackie; K M Caron
Journal:  Cytokine       Date:  2018-09       Impact factor: 3.861

6.  Structural Features of an Extended C-Terminal Tail Modulate the Function of the Chemokine CCL21.

Authors:  Natasha A Moussouras; Gertrud M Hjortø; Francis C Peterson; Martyna Szpakowska; Andy Chevigné; Mette M Rosenkilde; Brian F Volkman; Michael B Dwinell
Journal:  Biochemistry       Date:  2020-03-26       Impact factor: 3.162

7.  Kinetics of CXCL12 binding to atypical chemokine receptor 3 reveal a role for the receptor N terminus in chemokine binding.

Authors:  Martin Gustavsson; Douglas P Dyer; Chunxia Zhao; Tracy M Handel
Journal:  Sci Signal       Date:  2019-09-10       Impact factor: 8.192

8.  Differential activity and selectivity of N-terminal modified CXCL12 chemokines at the CXCR4 and ACKR3 receptors.

Authors:  Agnieszka Jaracz-Ros; Guillaume Bernadat; Pasquale Cutolo; Carmen Gallego; Martin Gustavsson; Erika Cecon; Françoise Baleux; Irina Kufareva; Tracy M Handel; Françoise Bachelerie; Angélique Levoye
Journal:  J Leukoc Biol       Date:  2020-05-06       Impact factor: 4.962

9.  Paradoxical anxiolytic effect of the 'bath salt' synthetic cathinone MDPV during early abstinence is inhibited by a chemokine CXCR4 or CCR5 receptor antagonist.

Authors:  Steven J Simmons; Chicora F Oliver; Nicholas S McCloskey; Allen B Reitz; Sunil U Nayak; Mia N Watson; Scott M Rawls
Journal:  Drug Alcohol Depend       Date:  2021-11-27       Impact factor: 4.492

Review 10.  Latest update on chemokine receptors as therapeutic targets.

Authors:  Wing Yee Lai; Anja Mueller
Journal:  Biochem Soc Trans       Date:  2021-06-30       Impact factor: 5.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.